



**Yale University School of Medicine**

Reproductive and Placental Research Unit  
Department of Obstetrics and Gynecology  
15 York Street, LCI 803  
New Haven, Connecticut 06510 &  
161 Ford Road, Woodbridge, CT 06525  
203 785-3854  
203 785-7642 (lab), 203 785-4477 (Fax)  
<http://klimanlabs.yale.edu>  
[harvey.kliman@yale.edu](mailto:harvey.kliman@yale.edu)

*Harvey J. Kliman, M.D., Ph.D.*

**CLIA #s 07D1029962/07D1062397; State of Connecticut Laboratory #s CL-0641/0653**

**8/14/2015**

***Via email and First Class Mail***

XX, MD

XX

XX

**Re: XX, Bx#: XX**

Dear Dr. XX,

We have completed our Endometrial Function Test® (EFT®) analysis of your patient's mock cycle biopsy that you performed on **7/17/2015** and that we received on **7/27/2015**. Our EFT results are as follows:

Clinical BT: **O** Clinical Date: **16** Cycle day by LH surge (d13): Cycle day by P (1<sup>st</sup> full day = d14): **16**

***Histologic Dating***

Overall (stromal) Date: **16.5**

(normal is within 2 days of cycle day)

Gland Date:

(dating of dyssynchronous glands, if present)

% Glands at Date:

(upper limit of normal is < 30% dyssynchronous glands)

**Dating comments:**


**Apoptotic figures:** None identified. **Mitotic figures:** Normal numbers noted.

Patient's age: 38 Patient's BMI: 21 Gest Hx: G0 P SAB Bchm Prem Ect ART Hx: IVF2 FET IUI Don


**Endometrial Function Test® (EFT®) Panel**

1° Antibody	Result	% Glands MAG Positive	Gland Cytoplasm	Gland Nuclei	Comment	
CycE	pos		50	20	Pattern is more consistent with cycle day 17-18.	▲
p27-D	pos		0	20	Pattern is more consistent with cycle day 17-18.	
PgR	pos		0	90	Normal for histologic dating.	▼


### Control and Patient Photomicrographs




HE Control




MAG Control




Cyclin E Control



Patient's HE



Patient's MAG or Other Image



Patient's Cyclin E

The top row of images are cycle day specific controls for standard H&E staining (left), MAG reactivity (center) and cyclin E (right). The bottom row of images are from our studies of your patient. Representative areas have been chosen and may not reflect all aspects of our findings. Please note that patients who are not blood group A or AB will not have a MAG image in the above results. If warranted, other images—which will be described below—may be found in the middle bottom row. Please refer to the table on the first page, as well as the narrative comments below, for our interpretation of these results.

#### **Interpretation**

Histologically this biopsy is very close to the cycle day as determined by P administration.

PR is normal for histologic dating.

However, both cyclin E and p27 are advanced (see lower middle image), being more consistent with cycle day 17-8. This pattern is consistent with either a too premature P action, or a too potent P response to an appropriate amount of P.

Full interpretation awaits analysis of the second biopsy of this cycle.

This test was developed and its performance characteristics determined by the Reproductive and Placental Research Unit, Yale University. It has not been cleared or approved by the U.S. Food and Drug Administration. Please note that the FDA does not require tests such as the EFT® to be cleared or approved.

Sincerely,

Harvey Kliman, M.D., Ph.D.